trovafloxacin (trovan) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Trovafloxacin is a broad spectrum antibiotic that inhibits DNA supercoiling in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It is not used widely due to the risk of hepatotoxicity. It tends to have better gram-positive bacterial coverage and less gram-negative coverage than the previous fluoroquinolones. Mechanism of action of fluoroquinolones including trovafloxacin is different from that of penicillins, cephalosporins, aminoglycosides, macrolides, and tetracyclines. Therefore fluoroquinolones may be active against pathogens that are resistant to these antibiotics. Trovafloxacin has in vitro activity against a wide range of gram-negative and gram-positive aerobic and anaerobic microorganisms. The bactericidal action of trovafloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription, and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. Trovafloxacin is used for the treatment of infections caused by susceptible strains of the designated microorganisms in uncomplicated urethral gonorrhea in males and endocervical and rectal gonorrhea in females caused by Neisseria gonorrhoeae as well as non gonoccocal urethritis and cervicitis due to Chlamydia trachomatis. Recalled from the market worldwide due to the risk of fatal liver failure.   NCATS

Chemistry

  • SMILES: N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12
  • InChIKey: WVPSKSLAZQPAKQ-CDMJZVDBSA-N
  • Mol. Mass: 416.36
  • ALogP: 1.89
  • ChEMBL Molecules:
    trovafloxacin  
    trovafloxacin mesylate  
More Chemistry

Pharmacology

Combination drugs

( azithromycin (zithromax), trovafloxacin (trovan) )

Alternative names

cp 99219 | cp 99,219 | cp-99219 | cp-99,219 | cp-9921927 | cp-99219-27 | trovafloxacin | trovafloxacin acid | trovafloxacin mesilate | trovafloxacin mesylate | trovafloxacin sulfate | trovan

Organizations (6)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (3)


 

Intraabdominal Infections (approved 1997)

Pneumonia (approved 1997)

Skin Diseases, Infectious (approved 1997)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Bacteremia (Phase 4)

Carcinoma, Renal Cell (Phase 2)

Endocarditis (Phase 4)

Sepsis (Phase 4)

Staphylococcus aureus (Phase 4)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue